Journal
MICROORGANISMS
Volume 9, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms9112342
Keywords
pneumococcal vaccine; PCV13; PPSV23; invasive pneumococcal disease; streptococcus pneumonia
Categories
Ask authors/readers for more resources
Pneumococcal disease is a global burden with high mortality rates. The use of pneumococcal vaccines in children has been effective, but vaccination for at-risk individuals aged 19-64 requires careful consideration due to insufficient evidence.
Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages worldwide. The immunization program of the pneumococcal conjugate vaccine (PCV) in children has decreased pneumococcal disease incidence in several countries. However, there are several problems regarding the pneumococcal vaccine, such as indications for immunocompetent persons with underlying medical conditions with a risk of pneumococcal disease, the balance of utility and cost, i.e., cost-effectiveness, vaccine coverage rate, serotype replacement, and adverse events. Especially for individuals aged 19-64 at risk of pneumococcal disease, physicians and vaccine providers should make a rational decision whether the patients should be vaccinated or not, since there is insufficient evidence supporting it. We describe this review regarding topics and problems regarding pneumococcal vaccination from the clinician's point of view.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available